Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Inventory (2022 - 2025)

BioXcel Therapeutics has reported Inventory over the past 4 years, most recently at $722000.0 for Q4 2025.

  • Quarterly results put Inventory at $722000.0 for Q4 2025, up 6.33% from a year ago — trailing twelve months through Dec 2025 was $722000.0 (up 6.33% YoY), and the annual figure for FY2025 was $722000.0, up 6.33%.
  • Inventory for Q4 2025 was $722000.0 at BioXcel Therapeutics, up from $459000.0 in the prior quarter.
  • Over the last five years, Inventory for BTAI hit a ceiling of $2.7 million in Q2 2024 and a floor of $459000.0 in Q3 2025.
  • Median Inventory over the past 4 years was $1.5 million (2022), compared with a mean of $1.4 million.
  • Biggest five-year swings in Inventory: soared 186.22% in 2023 and later plummeted 81.12% in 2025.
  • BioXcel Therapeutics' Inventory stood at $2.0 million in 2022, then rose by 0.3% to $2.0 million in 2023, then crashed by 65.9% to $679000.0 in 2024, then grew by 6.33% to $722000.0 in 2025.
  • The last three reported values for Inventory were $722000.0 (Q4 2025), $459000.0 (Q3 2025), and $506000.0 (Q2 2025) per Business Quant data.